<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03705117</url>
  </required_header>
  <id_info>
    <org_study_id>V56503</org_study_id>
    <nct_id>NCT03705117</nct_id>
  </id_info>
  <brief_title>Open-label V565 Target Engagement Study</brief_title>
  <official_title>An Open-label Exploratory Study in Patient Volunteers With Ulcerative Colitis (UC), to Investigate Lamina Propria Presence and Evidence of Biological Effect of the Oral Domain Antibody V565</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VHsquared Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VHsquared Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to confirm that V565 enters inflamed tissue, binds to TNF and
      reduces inflammation after oral dosing to patients with IBD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-site, open-label study in up to 6 patients treated for up to 7 days with sigmoidoscopy
      and biopsies before and after treatment period to determine biological activity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Actual">October 24, 2017</completion_date>
  <primary_completion_date type="Actual">October 24, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of phosphorylation in mucosal biopsies</measure>
    <time_frame>After 7 days oral treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of drug in mucosal biopsies</measure>
    <time_frame>After 7 days oral treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>V565</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V565 orally three times daily for up to 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V565</intervention_name>
    <description>Capsules for oral administration</description>
    <arm_group_label>V565</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of UC for 12 months or more

          -  Distal disease, accessible by flexible sigmoidoscopy

          -  Mild to moderate UC as defined as Mayo score between 3 - 10 with Mayo endoscopic sub
             score ≥1

        Exclusion Criteria:

          -  A known hypersensitivity to any of the inactive ingredients of the study treatment

          -  A diagnosis of any IBD except UC

          -  Isolated proctitis

          -  Stool culture positive for C. difficile or other enteric infection

          -  Untreated tuberculosis (TB); positive QuantiFERON-TB Gold Test result (performed by
             Central Laboratory)

          -  Evidence of previous or present hepatitis B or C infection

          -  Known severe viral infection within six weeks prior to Visit 1

          -  Current use of topical mesalazine or anti-infectives for serious infection (or within
             1 week)

          -  Anti-TNFα therapy other than the study drug

          -  Parenteral or enteral nutrition therapy

          -  Current use of any biologic agent

          -  Primary failure or secondary loss of response (LOR) to use of a TNFα inhibitor

          -  Contraindication to TNFα inhibitor

          -  Clinically significant abnormal laboratory test result at screening

          -  Taken an investigational drug within 3 months or 5 half-lives (whichever is longer)
             prior to the first dose in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suhail Nurbhai, MBChB</last_name>
    <role>Study Director</role>
    <affiliation>VHsquared Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>October 12, 2018</last_update_submitted>
  <last_update_submitted_qc>October 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

